Agency Information Collection Activities; Proposed Collection; Comment Request; State Enforcement Notifications, 69742-69743 [2011-29058]
Download as PDF
69742
Federal Register / Vol. 76, No. 217 / Wednesday, November 9, 2011 / Notices
the functions under Sections 8 & 15 of
the Small Business Act. The OSDBU
provides leadership, policy, guidance
and supervision, as well as coordinating
short- and long-range strategic planning
to assure that small business vendors
have a fair opportunity to compete for
and receive business with the
Department. The Office also provides
technical assistance to the Department’s
OPDIVs and STAFFDIVs; reviews and
evaluates planned procurements to
ensure that small businesses are given
thorough consideration; evaluates
effectiveness of the small business
programs and processes; develops
pertinent HHS-wide policies, guidance,
and performance standards; maintains
Departmental small business reports;
and conducts special Departmental
initiatives related to small and socioeconomic business concerns. The
OSDBU manages the development and
implementation of appropriate outreach
programs aimed at heightening the
awareness of the small business
community to the contracting
opportunities available within HHS.
The OSDBU provides input for
coordinated Department positions on
proposed legislation and Government
regulations on matters affecting
cognizant small socioeconomic business
programs. It also serves as the focal
point for coordinating ASFR’s response
to cross-cutting Freedom of Information
Act (FOIA) requests, audits, and
activities related to small business
related efforts and programs.
Dated: November 2, 2011.
E.J. Holland, Jr.,
Assistant Secretary for Administration.
[FR Doc. 2011–28964 Filed 11–8–11; 8:45 am]
BILLING CODE 4150–24–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0797]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; State Enforcement
Notifications
AGENCY:
Food and Drug Administration,
emcdonald on DSK5VPTVN1PROD with NOTICES
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
reporting requirements contained in
existing FDA regulations governing
State enforcement notifications.
DATES: Submit either electronic or
written comments on the collection of
information by January 9, 2012.
ADDRESSES: Submit electronic
comments on the collection of
information to https://www.regulations.
gov. Submit written comments on the
collection of information to the Division
of Dockets Management (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852. All comments should be
identified with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, II, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
3793.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
SUMMARY:
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
State Enforcement Notifications—21
CFR 100.2(d) (OMB Control Number
0910–0275)—Extension
Section 310(b) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act)
(21 U.S.C. 337(b)) authorizes States to
enforce certain sections of the FD&C Act
in their own names but provides that
States must notify FDA before doing so.
Section 100.2(d) (21 CFR 100.2(d)) sets
forth the information that a State must
provide to FDA in a letter of notification
when it intends to take enforcement
action under the FD&C Act against a
particular food located in the State. The
information required under § 100.2(d)
will enable FDA to identify the food
against which the State intends to take
action and advise the State whether
Federal action has been taken against it.
With certain narrow exceptions, Federal
enforcement action precludes State
action under the FD&C Act.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR section
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
100.2(d) ................................................................................
1
1
1
10
10
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Mar<15>2010
18:04 Nov 08, 2011
Jkt 226001
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
E:\FR\FM\09NON1.SGM
09NON1
Federal Register / Vol. 76, No. 217 / Wednesday, November 9, 2011 / Notices
The estimated reporting burden for
§ 100.2(d) is minimal because
enforcement notifications are seldom
used by States. During the last 3 years,
FDA has not received any new
enforcement notifications; therefore, the
Agency estimates that one or fewer
notifications will be submitted
annually. Although FDA has not
received any new enforcement
notifications in the last 3 years, it
believes these information collection
provisions should be extended to
provide for the potential future need of
a State government to submit
enforcement notifications informing
FDA when it intends to take
enforcement action under the FD&C Act
against a particular food located in the
State.
Dated: November 4, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–29058 Filed 11–8–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
The Development and Evaluation of
Human Cytomegalovirus Vaccines;
Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
emcdonald on DSK5VPTVN1PROD with NOTICES
ACTION:
Notice of public workshop.
The Food and Drug Administration,
Center for Biologics Evaluation and
Research, the National Institutes of
Health, the National Institute of Allergy
and Infectious Diseases, the Centers for
Disease Control and Prevention, and the
National Vaccine Program Office are
announcing a public workshop entitled
‘‘The Development and Evaluation of
Human Cytomegalovirus Vaccines.’’ The
purpose of the public workshop is to
identify and discuss key issues related
to the development and evaluation of
human cytomegalovirus (HCMV)
vaccines. The public workshop will
include presentations on HCMV disease
and pathogenesis and issues related to
vaccine development.
Date and Time: The public workshop
will be held on January 10 and January
11, 2012, from 8:30 a.m. to 5:30 p.m.
Location: The public workshop will
be held at Lister Hill Center
Auditorium, National Institutes of
Health, Bldg. 38A, 8600 Rockville Pike,
Bethesda, MD 20894. Pre-registered
participants will receive additional
VerDate Mar<15>2010
18:04 Nov 08, 2011
Jkt 226001
information on parking and public
transportation with their email
registration confirmation.
Contact Person: Manen Bishop,
Center for Biologics Evaluation and
Research (HFM–43), Food and Drug
Administration, 1401 Rockville Pike,
Suite 200N, Rockville, MD 20852–1448,
(301) 827–2000, FAX: (301) 827–3079,
email: CBERTraining@fda.hhs.gov
(Subject line: HCMV Vaccine
Workshop).
Registration: Mail or fax your
registration information (including
name, title, firm name, address,
telephone, and fax numbers) to Manen
Bishop (see Contact Person) or email to
CBERTraining@fda.hhs.gov (Subject
line: HCMV Workshop Registration) by
December 12, 2011. There is no
registration fee for the public workshop.
Early registration is recommended
because seating is limited. Registration
on the day of the public workshop will
be provided on a space available basis
beginning at 8 a.m.
If you need special accommodations
due to a disability, please contact
Manen Bishop (see Contact Person) at
least 7 days in advance.
SUPPLEMENTARY INFORMATION: HCMV,
also known as human herpesvirus 5,
infects approximately half of the U.S.
population by adulthood. While most
infections are without symptoms, the
infection is lifelong. However, the
disease may become apparent in
children who were infected during
gestation (congenital HCMV) and in
infected individuals with weakened
immune systems. Congenital HCMV
infection causes mental retardation,
learning disabilities, hearing loss, vision
loss, and other disabilities. Patients
undergoing stem cell or solid-organ
transplants are at particularly high risk
for severe disease or death from HCMV
infection.
An effective vaccine could have a
significant impact on rates of congenital
anomalies and severe infections caused
by HCMV. However, efforts to develop
a vaccine against HCMV have not yet
been successful.
The public workshop will focus on
the status of knowledge about HCMV
biology and epidemiology and on
vaccine development strategies. Topics
for discussion will include: (1) HCMV
epidemiology and diagnosis, (2) HCMV
immunology and virology, (3)
manufacturers’ and regulators’
perspectives, (4) target populations for a
HCMV vaccine, (5) design of clinical
trials to study HCMV vaccines in the
setting of congenital HCMV and
transplants, and (6) next steps toward
development of HCMV vaccines.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
69743
Transcripts: Please be advised that as
soon as possible after a transcript of the
public workshop is available, it will be
accessible at: https://www.fda.gov/
BiologicsBloodVaccines/NewsEvents/
WorkshopsMeetingsConferences/
TranscriptsMinutes/default.htm.
Transcripts of the public workshop may
also be requested in writing from the
Division of Freedom of Information
(ELEM–1029), Food and Drug
Administration, 12420 Parklawn Dr.,
Element Bldg., Rockville, MD 20857.
Dated: November 3, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–29006 Filed 11–8–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Application for Collaboration
With the NIH Center for Translational
Therapeutics (NCTT)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
(insert name of NIH Institute or Center),
the National Institutes of Health (NIH)
will publish periodic summaries of
proposed projects to be submitted to the
Office of Management and Budget
(OMB) for review and approval.
Proposed Collection: Title:
Application for collaboration with the
NIH Center for Translational
Therapeutics (NCTT). Type of
Information Collection Request: NEW.
Need and Use of Information Collection:
Programs at the NCTT provide
opportunities to partner with and gain
access to both common and specifically
rare and neglected disease through a
variety of programs delivering assay
development, screening, hit to lead
chemistry, lead optimization, chemical
biology studies, drug development
capabilities, expertise, and clinical/
regulatory resources in a collaborative
environment with the goal of moving
promising therapeutics into human
clinical trials. NCTT uses an application
and evaluation process to select
collaborators. Selected investigators
provide the drug project starting points
and ongoing biological/disease expertise
throughout the project. Frequency of
Response: Four per year. Affected
Public: Research scientists. Type of
Respondents: Academic scientists,
industry, not-for-profits, government
SUMMARY:
E:\FR\FM\09NON1.SGM
09NON1
Agencies
[Federal Register Volume 76, Number 217 (Wednesday, November 9, 2011)]
[Notices]
[Pages 69742-69743]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-29058]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0797]
Agency Information Collection Activities; Proposed Collection;
Comment Request; State Enforcement Notifications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on reporting requirements
contained in existing FDA regulations governing State enforcement
notifications.
DATES: Submit either electronic or written comments on the collection
of information by January 9, 2012.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, II, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, (301) 796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
State Enforcement Notifications--21 CFR 100.2(d) (OMB Control Number
0910-0275)--Extension
Section 310(b) of the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 337(b)) authorizes States to enforce certain
sections of the FD&C Act in their own names but provides that States
must notify FDA before doing so. Section 100.2(d) (21 CFR 100.2(d))
sets forth the information that a State must provide to FDA in a letter
of notification when it intends to take enforcement action under the
FD&C Act against a particular food located in the State. The
information required under Sec. 100.2(d) will enable FDA to identify
the food against which the State intends to take action and advise the
State whether Federal action has been taken against it. With certain
narrow exceptions, Federal enforcement action precludes State action
under the FD&C Act.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden 1
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
100.2(d)........................................................... 1 1 1 10 10
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
[[Page 69743]]
The estimated reporting burden for Sec. 100.2(d) is minimal
because enforcement notifications are seldom used by States. During the
last 3 years, FDA has not received any new enforcement notifications;
therefore, the Agency estimates that one or fewer notifications will be
submitted annually. Although FDA has not received any new enforcement
notifications in the last 3 years, it believes these information
collection provisions should be extended to provide for the potential
future need of a State government to submit enforcement notifications
informing FDA when it intends to take enforcement action under the FD&C
Act against a particular food located in the State.
Dated: November 4, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-29058 Filed 11-8-11; 8:45 am]
BILLING CODE 4160-01-P